Comparison of Neuromuscular Blocking Effects and Reversibility of Cisatracurium versus Atracurium During Thyroid Surgery

Rana Faizan Asghar; Abdul hameed bhatti; Najaf Imtiaz; Jaffar ali; Muhammad Wasib; Ateeq ur Rehman

doi:10.51253/pafmj.v75i5.10591

Authors

Rana Faizan Asghar Department of Anesthesia, 1 Mountain Medical Battalion, Bagh Pakistan
Abdul hameed bhatti Department of Anesthesia, Pakistan Air Force Hospital, Islamabad Pakistan
Najaf Imtiaz Department of Anesthesia, Combined Military Hospital, Dera Nawab Sahib/National University of Medical Sciences (NUMS) Pakistan
Jaffar ali Office of Deputy Director, Barkhan Pakistan
Muhammad Wasib Department of Anesthesia, Combined Military Hospital, Nowshera/National University of Medical Sciences (NUMS) Pakistan
Ateeq ur Rehman Department of Anesthesia, Combined Military Hospital, Skardu/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v75i5.10591

Keywords:

Anesthesia, Atracurium, Cisatracurium, Neuromuscular blocking effects, Reversibility

Abstract

Objective: To measure the neuromuscular blocking effects and reversibility of Cisatracurium (0.15mg/kg) with Atracurium (0.5mg/kg) during thyroid surgery.

Study Design: Quasi-experimental study.

Place and Duration of Study: Department of Anesthesia, Combined Military Hospital, Peshawar, Pakistan from Sep 2022 to Apr 2023.

Methodology: The present study was conducted on sixty patients undergoing thyroid surgery of age ranges from 20-65 years of both gender belonging to American Society of Anesthesiologists (ASA) I and II were included. All the patients were randomly divided into two equal Groups. Patients in Group-A received Atracurium (0.5 mg/kg) while in Group-B, received Cisatracurium (0.15 mg/kg). Patients were intubated three minutes after administration of Neuromuscular Blocking Agents (NMBAs). The outcomes in terms of time for onset of action, intubation conditions and reversibility were recorded.

Results: The mean time for onset of action was 4.67±0.88 minutes in Group-A while 2.37±0.76 minutes in Group-B with p-value of 0.001. In Group-A, the mean reversibility time was 41.80±1.69 minutes while 45.33±1.27 minutes in Group-B with p-value of 0.001. Intubating conditions assessed clinically were excellent in 10(33.33%), good in 09(30.0%) and poor in 11(36.67%) in Group-A whereas, in Group-B, excellent in 13(43.33%), good in 10(33.33%) and poor in 7(23.33%).

Conclusion: This study concluded that Cisatracurium (0.15mg/kg) is more effective Neuromuscular Blocking Agent (NMBA) than Atracurium (0.5mg/kg) in patients under general anesthesia.

Downloads

Download data is not yet available.

References

1. Brown EN, Lydic R, Schiff ND. General anesthesia, sleep, and coma. N Engl J Med 2010; 363(27): 2638-2650.

https://doi.org/10.1056/NEJMra0808281

2. Azeem A, Khokhar A, Mumal S, Akram E, Lodhi S. Inhibition of effects of acetylcholine at neuromuscular junction by omeprazole. Pak Armed Forces Med J 2022; 16(10): 43-45.

https://doi.org/10.53350/pjmhs22161043

3. Bonhomme V, Staquet C, Montupil J, Defresne A, Kirsch M, Martial C.et al. General anesthesia: A probe to explore consciousness. Front. Syst. Neurosci 2019; 13(36): 1-15.

https://doi.org/10.3389/fnsys.2019.00036

4. Shaikh SA, Jadhav AB, Patil AR, Shahsrabudhe AD. Efficacy of different doses of Cisatracurium for intubation during surgeries under general anaesthesia- A Randomiaed clinical study. J Clin Diagnostic Res 2022; 16(23): 1-4.

https://doi.org/10.7860/JCDR/2022/50991.16061

5. Sarah K, Mary E, Adrain W, Parth P, Jennifer S. Impact of a standardized dosing and titration protocol on cisatracurium requirements for ARDS. Crit Care Med 2020; 48(1): 531.

https://doi.org/10.1097/01.ccm.0000643348.83871.aa

6. Petitpain N, Argoullon L, Masmoudi K, Fedrizzi S, Cottin J, Latarche C. et al. Neuromuscular blocking agents induced anaphylaxis: Results and trends of a French pharmacovigilance survey from 2000 to 2012. Allergy 2018; 73(11): 2224-33.

https://doi.org/10.1111/all.13456

7. Martini CH, Boon M, Bevers RF, Aarts LP, Dahan A. Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. Br J Anaesth 2014; 112(3): 498-505.

https://doi.org/10.1093/bja/aet377

8. Narang D, Chaurasia A, Kumar G, Upadhyay MK. Comparative study to evaluate equipotent doses of cisatracurium and atracurium in patients undergoing abdominal laparoscopic surgery. Anaesth Pain Intensive Care 2021; 25(5): 667–671.

https://doi.org/10.35975/apic.v25i5.1618

9. Ali HH, Savarese JJ. Monitoring of neuromuscular function. Anesthesiology 1976; 45(2): 216-249.

https://doi.org/10.1097/00000542-197608000-00009

10. Brull SJ, Meistelman C. Pharmacology of Neuromuscular Blocking Drugs. In: Gropper MA, editor. Miller’s Anesthesia, 9th ed. Philadelphia: Elsevier; 2020.

11. Mertes PM, Laxenaire MC, Alla F. Anaphylactic and anaphylactoid reactions occurring during anaesthesia in France in 1999-2000. Anesthesiology 2003; 99(3): 536-545.

https://doi.org/10.1097/00000542-200309000-00007

12. El-Kasaby AM, Atef HM, Helmy AM, El-Nasr MA. Cisatracurium in different doses versus atracurium during general anesthesia for abdominal surgery. Saudi J Anaesth 2010; 4(3): 152-157.

https://doi.org/10.4103/1658-354X.71571

13. Kaur H, Attri JP, Chatrath V, Kaur H, Kaur J. Recovery profile if atracurium versus cisatracurium. J Clin Diag Res 2018; 12(2): 9-https://doi.org/10.7860/JCDR/2018/30686.11190

14. Mertes PM, Laxenaire MC, Alla F. Anaphylactic and anaphylactoid reactions occurring during anaesthesia in France in 1999-2000. Anesthesiology 2003; 99(3): 536-545.

https://doi.org/10.1097/00000542-200309000-00007

15. Bartkowski RR, Witknowski TA, Azad S, Lessin J, Marr A. Rocuronium onset of action: a comparison with atracurium and vecuronium. Anesth Analg 1993; 77(3): 574-578.

https://doi.org/10.1213/00000539-199309000-00025

16. Haines MA. Comparison of onset time, duration of action and fade characteristics of atracurium and vecuronium. ANNA J 1993; 61(6): 592-596.

17. Bergeron L, Bevan DR, Berrill A, Kahwaji R, Varin F. Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. Anesthesiology 2001; 95(2): 314-323.

https://doi.org/10.1097/00000542-200108000-00010

18. Shang Guan W, Lian Q, Li J, Gao F. Clinical pharmacology of cisatracurium during nitrous oxide-propofol anesthesia in children. J Clin Anesth 2008; 20(6): 411-414.

https://doi.org/10.1016/j.jclinane.2008.03.011

19. Bluestein LS, Stinson LW Jr, Lennon RL, Quessy SN, Wilson RM. Evaluation of cisatracurium, a new neuromuscular blocking agent for tracheal intubation. Can J Anaesth 1996; 43(9): 925-931.

https://doi.org/10.1007/BF03011806

20. Anjali C, Radha KR, Biji KP. Prospective cohort study comparing varying doses of Cisatracurium and atracurium on intubating conditions in patients undergoing laparoscopic cholecystectomy. J Clin Diagn Res 2021; 15(4): 11-13.

https://doi.org/10.7860/JCDR/2021/48203.14762